<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articlesâ€”Melanoma
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Oct 17, Ravi Amaravadi, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert's review, here are the must-read articles for every oncologist
  about patients with melanoma.</p>

  <p>1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in
  melanoma with BRAF V600E mutation. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1103782">N Engl J Med.
  2011;364(26):2507-2516</a>. <strong>Free</strong></p>

  <p>2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of Mutated, Activated BRAF in
  Metastatic Melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1002011">N Engl J Med.
  2010;363(9):809-819</a>. <strong>Free</strong></p>

  <p>3. Hodi, FS, O&acirc;&euro;&trade;Day SJ, McDermott DF, et al. Improved Survival
  with Ipilimumab in Patients with Metastatic Melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1003466">N Engl J Med.
  2010;363(8):711-723</a>. <strong>Free</strong></p>

  <p>4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for
  previously untreated metastatic melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1104621">N Engl J Med.
  2011;364(26):2517-2526</a>. <strong>Free</strong></p>

  <p>5. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic
  melanoma: a multicenter, open-label, phase 3 randomised controlled trial. <a target=
  "_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S014067361260868X">Lancet.
  2012;380(9839):358-365</a>.</p>

  <p>6. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic,
  pharmacodynamics, and efficacy data for the oral MEK inhibitor trametinib: a phase 1
  dose-escalation trial. <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S147020451270270X">Lancet Oncol.
  2012;13(8):773-781</a>.</p>

  <p>7. Topalian SL, Hodi FS, Brahmer RJ, et al. Safety, activity, and immune correlates
  of anti-PD-1 antibody in cancer. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1200690">N Engl J Med.
  2012;366(26):2443-2454</a>.</p>

  <p>8. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-1 antibody
  in patients with advanced cancer. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1200694">N Engl J Med.
  2012;366(26):2455-2465</a>.</p>

  <p>9. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced
  melanoma treated with vemurafenib. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1112302">N Engl J Med.
  2012;366:707-714</a>. <strong>Free</strong></p>

  <p>10. Balch CM, Gersenwals JE, Soong SJ, et al. Final version of 2009 AJCC melanoma
  staging and classification. <a target="_blank" href=
  "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035/">J Clin Oncol.
  2009;27(36):6199-6206</a>. <strong>Free</strong></p>

  <p>11. Carvajal, RD, Antonescu CR, Wolchok, JD, et al. KIT as a therapeutic target in
  metastatic melanoma. <a target="_blank" href=
  "http://jama.jamanetwork.com/article.aspx?articleid=900719">JAMA.
  2011;305(22):2327-2334</a>. <strong>Free</strong></p>

  <p>12. Falchook, GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor
  trametinib in patients with advanced melanoma: a phase I dose-escalation trial.
  <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S1470204512702693">Lancet Oncol.
  2012;13(8):782-789</a>.</p>

  <p>13. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma,
  untreated brain metastases, and other solid tumors: a phase I dose-escalation trial.
  <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S0140673612603985">Lancet.
  2012;379(9829):1893-1901</a>.</p>

  <p>14. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in
  BRAF-mutated melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1203421">N Engl J Med.
  2012;367(2):107-114</a>.</p>

  <p>15. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for
  thin cutaneous melanoma. <a target="_blank" href=
  "http://archsurg.jamanetwork.com/article.aspx?articleid=595029">Arch Surg.
  1991;126(4):438-441</a>.</p>

  <p>16. Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease
  progression after local recurrence of melanoma. <a target="_blank" href=
  "http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0142%2820000301%2988:5%3C1063::AID-CNCR17%3E3.0.CO;2-E/pdf">
  Cancer. 2000;88(5):1063-1071</a>.</p>

  <p>17. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the
  efficacy of routine elective lymphadenectomy in management of malignant melanoma.
  Preliminary results. <a target="_blank" href=
  "http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%28197803%2941:3%3C948::AID-CNCR2820410324%3E3.0.CO;2-Z/pdf">
  Cancer. 1978;41(3):948-956</a>.</p>

  <p>18. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection
  in stage I melanoma of the skin of the lower extremities. <a target="_blank" href=
  "http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819820601%2949:11%3C2420::AID-CNCR2820491133%3E3.0.CO;2-2/pdf">
  Cancer. 1982;49(11):2420-2430</a>.</p>

  <p>19. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph
  node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.
  <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1235362/">Ann
  Surg. 1996;224(3):255-263</a>. <strong>Free</strong></p>

  <p>20. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon
  study in WHO melanoma programme. <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S0140673694900302">Lancet.
  1994;343(8902):913-914</a>.</p>

  <p>21. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of
  regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma
  Programme. <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S0140673697082603">Lancet.
  1998;351(9105):793-796</a>.</p>

  <p>22. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for
  localized, high-risk limb melanoma: results of a multicenter randomized phase III
  trial. European Organization for Research and Treatment of Cancer Malignant Melanoma
  Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial
  15, and the North American Perfusion Group Southwest Oncology Group-8593. <a target=
  "_blank" href="http://jco.ascopubs.org/content/16/9/2906.abstract">J Clin Oncol.
  1998;16(9):2906-2912</a>.</p>

  <p>23. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of
  hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus
  tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
  <a target="_blank" href="http://jco.ascopubs.org/content/24/25/4196.full.pdf+html">J
  Clin Oncol. 2006;24(25):4196-4201</a>.</p>

  <p>24. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical
  trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.
  <a target="_blank" href="http://jco.ascopubs.org/content/13/11/2776.abstract">J Clin
  Oncol. 1995;13(11):2776-2783</a>.</p>

  <p>25. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b
  in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. <a target=
  "_blank" href="http://jco.ascopubs.org/content/18/12/2444.full.pdf+html">J Clin Oncol.
  2000;18(12):2444-2458</a>.</p>

  <p>26. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk
  melanoma: the AIM HIGH Study&ndash;United Kingdom Coordinating Committee on Cancer
  Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in
  high-risk resected malignant melanoma. <a target="_blank" href=
  "http://jco.ascopubs.org/content/22/1/53.full.pdf+html">J Clin Oncol.
  2004;22(1):53-61</a>.</p>

  <p>27. Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with
  intermediate doses of interferon alfa 2b versus observation in patients with stage
  IIb/III melanoma (EORTC 18952): randomised controlled trial. <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S014067360567482X">Lancet.
  2005;366(9492):1189-1196</a>.</p>

  <p>28. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated
  interferon alfa-2b versus observation alone in resected stage III melanoma: final
  results of EORTC 18991, a randomised phase III trial. <a target="_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S0140673608610338">Lancet.
  2008;372(9633):117-126</a>.</p>

  <p>29. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or
  without dacarbazine compared with surgery alone: a prospective-randomized phase III
  DeCOG trial in melanoma patients with regional lymph node metastasis. <a target=
  "_blank" href="http://annonc.oxfordjournals.org/content/19/6/1195.full.pdf+html">Ann
  Oncol. 2008;19(6):1195-1201</a>. <strong>Free</strong></p>

  <p>30. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon
  alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without
  clinically detectable node metastases. French Cooperative Group on Melanoma. <a target=
  "_blank" href=
  "http://www.sciencedirect.com/science/article/pii/S014067369712445X">Lancet.
  1998;351(9120):1905-1910</a>.</p>

  <p>31. Gr&Atilde;&frac14;nhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat
  isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple
  in-transit metastases in patients with prior isolated limb perfusion failure.
  <a target="_blank" href=
  "http://www.springerlink.com/content/j250600p77r62381/?MUD=MP">Ann Surg Oncol.
  2005;12(8):609-615</a>.</p>

  <p>32. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b
  significantly prolongs relapse-free and overall survival compared with the
  GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of
  intergroup trial E1694/S9512/C509801. <a target="_blank" href=
  "http://jco.ascopubs.org/content/19/9/2370.full.pdf+html">J Clin Oncol.
  2001;19(9):2370-2380</a>.</p>

  <p>33. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant
  therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology
  Group Trial EST 1684. <a target="_blank" href=
  "http://jco.ascopubs.org/content/14/1/7.abstract">J Clin Oncol.
  1996;14(1):7-17</a>.</p>

  <p>34. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic
  melanoma lysate vaccine with low-dose interferon alfa-2b compared with high dose
  interferon alfa-2b for resected stage III cutaneous melanoma. <a target="_blank" href=
  "http://jco.ascopubs.org/content/25/15/2078.full.pdf+html">J Clin Oncol.
  2007;25(15):2078-2085</a>.</p>

  <p>35. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial
  of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
  <a target="_blank" href="http://jco.ascopubs.org/content/17/9/2745.long">J Clin Oncol.
  1999;17(9):2745-2751</a>.</p>

  <p>36. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of
  temozolomide versus dacarbazine in the treatment of patients with advanced metastatic
  malignant melanoma. <a target="_blank" href=
  "http://jco.ascopubs.org/content/18/1/158.full.pdf+html">J Clin Oncol.
  2000;18(1):158-166</a>. Errata: <a target="_blank" href=
  "http://jco.ascopubs.org/content/18/11/2351.full.pdf+html">J Clin Oncol.
  2000;18(11):2351-2352</a>.</p>

  <p>37. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib
  mesylate in patients with metastatic melanoma harboring c-Kit mutation or
  amplification. <a target="_blank" href=
  "http://jco.ascopubs.org/content/29/21/2904.long">J Clin Oncol.
  2011;29(21):2904-2909</a>.</p>

  <p>38. Wang XY, Zuo D, Sarkar D, et al. Blockade of cytotoxic T-lymphocyte antigen-4 as
  a new therapeutic approach for advanced melanoma. <a target="_blank" href=
  "http://informahealthcare.com/doi/abs/10.1517/14656566.2011.629187">Expert Opin
  Pharmacother. 2011;12(17):2695-2706</a>.</p>

  <p>39. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and
  interleukin-2 in patients with advanced melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1012863">N Engl J Med.
  2011;364(22):2119-2127</a>. <strong>Free</strong></p>

  <p>40. Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of
  biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high
  risk for melanoma recurrence. <a target="_blank" href=
  "http://journals.lww.com/melanomaresearch/Fulltext/2009/02000/A_randomized_phase_III_trial_of_biochemotherapy.7.aspx">
  Melanoma Res. 2009;19(1):42-49</a>. <strong>Free</strong></p>

  <p>41. Wolchok JD, Hoos A, O&acirc;&euro;&trade;Day S, et al. Guidelines for the
  evaluation of immune therapy activity in solid tumors: immune-related response
  criteria. <a target="_blank" href=
  "http://clincancerres.aacrjournals.org/content/15/23/7412.full.pdf+html">Clin Cancer
  Res. 2009;15(23):7412-7420</a>. <strong>Free</strong></p>

  <p>42. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal
  effect in a patient with melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa1112824">N Engl J Med.
  2012;366(10):925-931</a>. <strong>Free</strong></p>

  <p>43. Pflugfelder A, Eigentler TK, Keim U, et al. Effectiveness of carboplatin and
  paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
  <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040212/">PLoS
  One. 2011;6(2):e16882</a>. <strong>Free</strong></p>

  <p>44. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of
  treatment with high-dose interleukin-2 either alone or in combination with interferon
  alfa-2a in patients with advanced melanoma. <a target="_blank" href=
  "http://jco.ascopubs.org/content/11/10/1969.abstract">J Clin
  Oncol.1993;11(10):1969-1977</a>.</p>

  <p>45. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent
  biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon
  alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic
  malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology
  Group. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645104/">J
  Clin Oncol. 2008;26(35):5748-5754</a>. <strong>Free</strong></p>

  <p>46. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal
  observation in melanoma. <a target="_blank" href=
  "http://www.nejm.org/doi/full/10.1056/NEJMoa060992">N Engl J Med.
  2006;355(13):1307&ndash;1317</a>. <strong>Free</strong></p>

  <p>47. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of
  interferon alfa-2b and interleukin-2 as adjuvant treatment for resected
  intermediate-and high-risk primary melanoma without clinically detectable node
  metastasis. <a target="_blank" href=
  "http://jco.ascopubs.org/content/21/15/2883.full.pdf+html">J Clin Oncol.
  2003;21(15):2883&ndash;2888</a>.</p>

  <p>48. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected,
  intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine:
  overall results of a randomized trial of the Southwest Oncology Group. <a target=
  "_blank" href="http://jco.ascopubs.org/content/20/8/2058.full.pdf+html">J Clin Oncol.
  2002;20(8):2058&ndash;2066</a>.</p>

  <p>49. Gimotty PA, Elder DE, Fraker DL, et al: Identification of high-risk patients
  among those diagnosed with thin cutaneous melanomas. <a target="_blank" href=
  "http://jco.ascopubs.org/content/25/9/1129.full.pdf+html">J Clin Oncol.
  2007;25(9):1129-1134</a>.</p>

  <p>50. Kesmodel SB, Karakousis GC, Botbyl JD, et al: Mitotic rate as a predictor of
  sentinel lymph node positivity in patients with thin melanomas. <a target="_blank"
  href="http://www.springerlink.com/content/p93801050323l628/">Ann Surg Oncol.
  2005;12(6):449-458</a>.</p>

  <p>51. Francken AB, Shaw HM, Thompson JF, et al: The prognostic importance of tumor
  mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long
  follow-up. <a target="_blank" href=
  "http://www.springerlink.com/content/da4tt9kq2guq3jnf/">Ann Surg Oncol.
  2004;11(4):426-433</a>.</p>

  <p>52. Busam KJ: The prognostic importance of tumor mitotic rate for patients with
  primary cutaneous melanoma. <a target="_blank" href=
  "http://www.springerlink.com/content/f560qcm5233a0n4y/">Ann Surg Oncol.
  2004;11(4):360-361</a>.</p>

  <p>53. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily
  pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
  <a target="_blank" href=
  "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131487/pdf/nihms286994.pdf">Clin Cancer
  Res. 2011;17(13):4550-4557</a>. <strong>Free</strong></p>

  <p>54. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients
  with metastatic melanoma. <a target="_blank" href=
  "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459355/">Curr Opin Immunol.
  2009;21(2):233</a>. <strong>Free</strong></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>